Guardant Health (GH) PT Raised to $180 at Stifel on Clean Beat and Raise Q2

Stifel analyst Daniel Arias raised the price target on Guardant Health (NASDAQ: GH) to $180.00 (from $130.00) while maintaining a Buy rating.

The analyst commented, "Q2 was another clean beat and raise quarter from Guardant. Revenue grew 44% to $335M with every line contributing: Oncology volumes accelerated to 63% y/y growth including >100% Reveal volume growth, and Shield volumes grew 50% q/q. The broad-based growth leaves little to pick at here. Looking ahead, with Screening now guided to 270k–285k tests and Oncology volume growth expectations raised to ~50% for the full year, we see upside opportunities vs consensus FY27 sales - with catalysts that can provide tailwinds well into next year: G360 Liquid ADLT pricing, ACS guideline inclusion, major commercial Shield coverage from UnitedHealth, and improved coverage and lower COGS for Shield driving increased sales and marketing efforts. Our TP goes to $180, and we remain Buy rated heading into 2H26."

You May Also Be Interested In

• Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
• United Airlines: expects to fly more than 3.4M customers between September 3-8
• Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg